Sana Biotechnology (SANA) Other Non-Current Liabilities (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Other Non-Current Liabilities data on file, last reported at $83.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 781.08% year-over-year to $83.2 million; the trailing twelve-month figure through Mar 2026 stood at $83.2 million (up 781.08% YoY), and the FY2025 full-year result was $10.6 million, up 7.11% from the prior year.
• Other Non-Current Liabilities grew to $83.2 million in Q1 2026, from $10.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $109.6 million in Q4 2023 to a low of $7.5 million in Q3 2024.
• A 5-year average of $62.3 million and a median of $65.9 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities plunged 90.97% in 2024 and jumped 781.08% in 2026, its largest moves.
• Tracing SANA's Other Non-Current Liabilities over 5 years: stood at $95.0 million in 2022, then grew by 15.33% to $109.6 million in 2023, then sank by 90.97% to $9.9 million in 2024, then gained by 7.11% to $10.6 million in 2025, then soared by 684.91% to $83.2 million in 2026.
• Business Quant data shows SANA's Other Non-Current Liabilities at $83.2 million in Q1 2026, $10.6 million in Q4 2025, and $7.9 million in Q3 2025.